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Objectives This study sought to assess the contemporary outcomes of patients with prior coronary
artery bypass graft (CABG) who present with moderate and high-risk acute coronary syndromes
(ACS) and are treated with an early invasive strategy and contemporary antithrombin regimens.
Background The prognosis of patients with ACS and prior CABG in relation to triage strategy and
contemporary antithrombotic regimens is unknown.
Methods In the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial, 2,475 of
13,764 patients (18.0%) with ACS managed with an early invasive strategy had previously undergone
CABG. Their outcomes were examined according to treatment and randomized antithrombin regimen.
Results Prior CABG was associated with older age, more frequent comorbidities, higher Thromboly-
sis In Myocardial Infarction risk score, and lower left ventricular ejection fraction. Patients with ver-
sus without prior CABG were less likely to undergo (repeat) CABG and were more likely to be man-
aged medically. At 1 year, patients with versus without prior CABG had higher rates of major
adverse cardiac events (MACE) (22.5% vs. 15.2%, p  0.0001) due to greater mortality (5.4% vs.
.9%, p  0.0001), myocardial infarction (10.0% vs. 6.8%, p  0.0001), and unplanned revasculariza-
ion (13.1% vs. 8.2%, p  0.0001). History of CABG was an independent predictor of MACE. The
-year MACE rates were not signiﬁcantly different after randomization to bivalirudin versus heparin
lus a glycoprotein IIb/IIIa inhibitor (odds ratio: 1.24, 95% conﬁdence interval: 0.90 to 1.70).
onclusions Despite the progress in the treatment of coronary artery disease, patients with prior
ABG and ACS have a poor prognosis, substantially worse than for those without prior CABG.
hereas bivalirudin monotherapy was an acceptable treatment for these patients, it did not im-
rove their prognoses. (J Am Coll Cardiol Intv 2012;5:919–26) © 2012 by the American College of
ardiology Foundation
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920Coronary artery bypass graft (CABG) was broadly intro-
duced in the 1970s, and since then has become one of the
most common surgical procedures in the United States (1).
However, despite successful revascularization and secondary
prevention measures, progression of atherosclerosis after
CABG occurs both in grafts and native coronary arteries,
resulting in significant morbidity and mortality, especially in
patients who present with acute coronary syndromes (ACS)
(2,3). Currently, an early invasive strategy is recommended
for management of such patients (4). Nonetheless, in previous
studies, patients with prior CABG and ACS reportedly have
poor prognoses, regardless of management strategy (5–7). The
outcomes of patients with prior CABG and ACS have not
recently been reported from a large-scale contemporary study,
and the optimal antithrombotic regimens have not been
identified. Therefore, we assessed the outcomes of patients
with a history of CABG presenting with ACS and undergoing
an early invasive approach from the ACUITY (Acute Cathe-
terization and Urgent Intervention Triage Strategy) trial.
Methods
Study design. The inclusion and
exclusion criteria and principal
results of the ACUITY trial
have been reported in detail else-
where (8–10). In brief, patients
18 years of age with symptoms
of unstable angina lasting 10
min within the preceding 24 h
were eligible if 1 or more of the
following criteria were met: new
ST-segment depression or tran-
sient elevation1 mm; troponin
or creatine kinase-myocardial
and elevation; known coronary artery disease; or all 4 other
IMI (Thrombolysis In Myocardial Infarction) unstable
ngina risk criteria were positive (8). Eligible patients were
andomized to the open-label use of 1 of 3 antithrombin
egimens started before angiography: heparin (either unfrac-
ionated or enoxaparin) plus a glycoprotein IIb/IIIa inhib-
tor (GPI); bivalirudin plus a GPI; or bivalirudin
onotherapy.
After mandatory angiography was performed within 72 h
f randomization, the patients were triaged according to
anagement by percutaneous coronary intervention (PCI),
ABG, or medical therapy. Aspirin and clopidogrel were
dministered as previously described (8–10). In patients
ndergoing PCI, the type of stent used was determined by
he operator’s discretion.
Information as to whether previous CABG was per-
ormed was collected by site investigators at the time of
Abbreviations
and Acronyms
ACS  acute coronary
syndromes(s)
CABG  coronary artery
bypass graft
GPI  glycoprotein IIb/IIIa
inhibitor
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
TIMI  Thrombolysis In
Myocardial Infarctiontudy enrollment.Clinical endpoints. The primary endpoint in ACUITY was
major adverse cardiac events (MACE) (which are death
from any cause, myocardial infarction [MI], or unplanned
revascularization for ischemia), non-CABG major bleeding,
and net adverse clinical events (MACE or major bleeding)
(8). A Clinical Events Committee blinded to treatment
assignment adjudicated all 30-day and 1-year primary end-
point and bleeding events.
Statistical analysis. Categorical variables were compared
with chi-square or Fisher exact tests. Continuous variables
are presented as medians with interquartile ranges and were
compared using the Kruskal-Wallis test. Thirty-day and
1-year outcomes are presented as Kaplan-Meier estimates
and were compared using log-rank tests. Multivariable
logistic regression was used to identify independent predic-
tors of outcomes in the entire ACUITY population adjust-
ing for age, sex, diabetic status, hypertension, current
smoking, prior MI, prior PCI, prior CABG, baseline
cardiac biomarker elevation, ST-segment deviation, baseline
estimated creatinine clearance (Cockcroft-Gault equation),
baseline anemia, left ventricular ejection fraction, anti-
thrombotic regimen randomization, and triage to PCI
versus (repeat) CABG versus medical management. A
forward stepwise algorithm was used to select significant
covariates from this list. In addition, separate models of
clinical outcomes were specifically created for patients with
prior CABG.
Results
Baseline clinical characteristics. Among the 13,819 patients
with ACS, information regarding CABG history was avail-
able in 13,764 (99.6%), 2,475 of whom (18.0%) had previously
undergone CABG. Patients with versus without prior CABG
had a significantly higher risk profile, except for ST-segment
changes and abnormal cardiac biomarkers, which were less
frequent in prior CABG patients (Table 1). A similar pro-
portion of ACS patients with and without prior CABG
were triaged to revascularization with PCI. However, treat-
ment with (repeat) CABG was much less common in
patients with prior CABG.
Clinical outcomes. Patients with versus without prior
CABG had significantly greater 30-day rates of MACE,
driven mainly by more frequent MI (Fig. 1A). Rates of
MACE in prior CABG patients remained higher at 1 year,
due to higher rates of mortality, MI, and unplanned
revascularization (Figs. 1B and 2) of both target and
nontarget vessels (6.9% vs. 5.0%, p  0.0009 and 5.6% vs.
4.1%, p  0.004, respectively).
Patients with prior CABG and ACS had a particularly high
rate (10.0%) of developing a new MI (apart from the present-
ing event) within 1 year. Of the 239 infarcts that occurred
within 1 year, approximately one-half (n  118) occurred
during the index hospitalization mainly due to revasculariza-
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921tion procedures, whereas the other half (n  121) occurred
during follow-up related to recurrent ischemia.
History of CABG was an independent predictor of
1-year MACE and its individual components, including
mortality (hazard ratio [HR]: 1.33; 95% confidence interval
[CI]: 1.03 to 1.71, p 0.028), MI (HR: 1.67; 95% CI: 1.41
to 1.97, p 0.0001), and unplanned revascularization (HR:
1.40; 95% CI: 1.21 to 1.62, p  0.0001) (Table 2).
Outcomes in the prior CABG group according to treatment.
Following angiography, the 2,475 patients with prior
CABG were treated by PCI (n  1,370; 55.4%), repeat
CABG (n  73; 2.9%), or medically (n  1,032; 41.7%).
mong those undergoing PCI, intervention was performed
n native arteries in 852 (62.2%), on bypass grafts in 552
40.3%), and on both in 34 (2.5%) patients. Among those
ndergoing repeat CABG, a median of 3.0 grafts were
laced, with arterial graft(s) used in 40 patients (54.8%).
hirteen patients (17.8%) had concurrent surgical proce-
Table 1. Baseline Clinical Data, Randomization Assignment,
and Triage Strategy in Patients With and Without History of CABG
Prior CABG
(n  2,475)
No Prior CABG
(n  11,289) p Value
Age, yrs 67 (58–74) 62 (53–71) 0.0001
Male 77.8 68.2 0.0001
Diabetes 37.3 26.1 0.0001
Hypertension 82.1 63.7 0.0001
Hyperlipidemia 80.6 52.0 0.0001
Current smoker 18.1 31.5 0.0001
Previous myocardial infarction 57.2 25.9 0.0001
History of PCI 57.6 34.8 0.0001
LVEF, % 52 (40–60) 57 (50–65) 0.0001
Anemia 22.8 15.6 0.0001
Chronic renal insufﬁciency 25.2 17.7 0.0001
Cardiac biomarker elevation 44.3 62.7 0.0001
ST-segment deviation 1 mm 29.7 36.1 0.0001
TIMI risk score
Low (0–2) 3.1 18.4 0.0001
Intermediate (3–4) 44.2 56.8 0.0001
High (5–7) 52.7 24.8 0.0001
Randomization to antithrombotic
medications
Unfractionated heparin  GPI 33.9 33.2 0.53
Bivalirudin  GPI 32.5 33.5 0.32
Bivalirudin alone 33.7 33.3 0.72
Treatment strategy
PCI 55.4 56.6 0.25
CABG 2.9 13.0 0.0001
Medical management 41.7 30.4 0.0001
Values are median (interquartile range) or percentages.
CABG coronary artery bypass graft; GPI glycoprotein IIb/IIIa inhibitor; LVEF left ventricle
ejection fraction; PCI percutaneous coronary intervention; TIMI Thrombolysis In Myocardial
Infarction.ures, including valvular and/or other nonspecified inter-vention. Among 1,032 patients triaged to medical manage-
ment, revascularization was declined due to the physician’s
or patient’s preference in 405 (39.2%) and in 15 (1.4%),
respectively, due to lesion anatomy considered amenable for
revascularization in 261 (25.3%), due to absence of significant
lesion in 152 (14.7%), and due to poor patient’s condition in 7
(0.7%) patients. The reason for not performing a revascular-
ization was not specified in 192 (18.6%) patients.
Prior CABG patients undergoing repeat CABG compared
with PCI or medical therapy had significantly higher 30-day
and 1-year rates of MI (both Q-wave and non–Q-wave) and
mortality (Table 3). Prior CABG patients undergoing PCI
compared with medical management had significantly higher
30-day and 1-year rates of MI, unplanned revascularization,
and non–CABG-related major bleeding.
Clinical outcomes stratified by history of CABG and man-
agement strategy are presented in Table 4. Prior CABG
patients treated by CABG or PCI, compared with patients
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Figure 1. Outcomes of Patients With and Without Prior CABG
at 30 Days and 1 Year
Outcomes of patients with and without prior coronary artery bypass graft
(CABG) at 30 days (A) and 1 year (B). MACE  major adverse cardiac
event(s); NACE  net adverse clinical event(s).
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922without prior CABG, had substantially higher rates of all
adverse events except major bleeding. Repeat versus first
CABG was also associated with more frequent CABG-related
reoperations for bleeding (4.2% vs. 1.4%, p 0.051) and blood
roduct transfusions (58.8% vs. 40.4%, p  0.003).
Among patients with prior CABG triaged to PCI,
ntervention on a graft compared with native vessel was
ssociated with higher 30-day rates of MI (both Q-wave MI
2.1% vs. 0.8%, p 0.04], non–Q-wave MI [9.4% vs. 5.4%,
 0.008]), and MACE (14.8% vs. 9.2%, p  0.002). At
year, MACE remained increased in patients after PCI of
rafts (33.1% vs. 21.9%, p  0.0001), due to higher rates of
ortality (6.6% vs. 3.6%, p  0.02), MI (Q-wave: 2.6% vs.
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Figure 2. 1-Year Mortality in Patients With and Without Prior CABG
CABG  coronary artery bypass graft.
Table 2. Multivariate Predictors of 1-Year MACE in the Entire
ACUITY Population
Variable
Logistic
Coefficient p Value
Hazard Ratio
(95% CI)
Triage to CABG vs. medical therapy 0.96 0.0001 2.61 (2.20, 3.10)
Triage to PCI vs. medical therapy 0.83 0.0001 2.29 (2.02, 2.60)
History of CABG 0.41 0.0001 1.51 (1.35, 1.70)
Baseline renal insufﬁciency 0.37 0.0001 1.45 (1.30, 1.61)
History of PCI 0.28 0.0001 1.32 (1.18, 1.48)
Baseline anemia 0.25 0.0001 1.28 (1.14, 1.44)
Hypertension 0.18 0.0011 1.20 (1.07, 1.33)
ST-segment deviation 1 mm 0.18 0.0003 1.20 (1.09, 1.32)
Baseline cardiac biomarker
elevation
0.17 0.0014 1.18 (1.07, 1.31)
ACUITY  Acute Catheterization and Urgent Intervention Triage Strategy; CI  confidenceinterval; MACEmajor adverse cardiac event(s); other abbreviations as in Table 1.0.8%, p  0.011; non–Q-wave: 16.2% vs. 7.8%, p  0.0001),
and unplanned revascularization (19.6% vs. 14.3%, p 0.053).
The 1-year mortality was significantly higher among
patients with prior CABG in whom the decision to be
treated with medical management was made because of
patient preference rather than physician guidance (20.6% vs.
5.4%, p  0.018). The same was true for 1-year MACE
(34.0% vs. 15.1%, p  0.046).
Randomized antithrombotic therapy. The main baseline
haracteristics among patients with prior CABG were well
atched among the 3 randomization arms (data not
hown). The 30-day and 1-year outcomes according to
andomization are presented in Figure 3. The multivariable
redictors of 30-day and 1-year MACE in patients with
rior CABG are shown in Figure 4. MACE at 30 days and
year were not significantly different after randomization to
ivalirudin compared with heparin plus a GPI.
iscussion
The main results of the present analysis are as follows.
1) Prior CABG is common in patients admitted for ACS.
2) Patients with prior CABG compared with those without
previous surgical revascularization are at increased adjusted
risk for ischemic events and 1-year mortality. 3) Bivalirudin
monotherapy was an acceptable treatment for these
patients, but did not improve their short-term or long-
term prognosis. 4) In patients with prior CABG and
ACS, revascularization with either PCI or repeat CABG
was associated with high 30-day and 1-year rates of MI
3.9% 
5.4% 
<0.001 
2325 2299 1680
10737 10675 7991
Log-Rank P= <.
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923bypass graft conduits), and triage to revascularization
versus medical therapy was an independent predictor of
1-year MACE.
Table 3. Clinical Outcomes of 2,475 Patients With Prior
Outcomes
PCI
(n  1,370)
Repea
(n 
At 30 days
Death 1.4 12
Myocardial infarction 8.7 21
Q-wave 1.2 4
Non–Q-wave 7.4 16
Unplanned revascularization 3.8 0
MACE 11.9 28
Non-CABG major bleeding 6.3 1
NACE 16.2 30
At 1 year
Death 5.3 13
Myocardial infarction 13.5 21
Q-wave 1.6 4
Non–Q-wave 12.1 16
Unplanned revascularization 17.3 12
MACE 27.8 39
Values are %.
ACS acute coronary syndromes; NACE net adverse clinical even
vs. medical management; other abbreviations as in Tables 1 and 2.
Table 4. Clinical Outcomes of Patients With Prior CABG Versus Without Pr
Outcomes
Patients Triaged to PCI
(n  7,773)
p Value
Prior CABG
(n  1,370)
No Prior CABG
(n  6,393)
R
At 30 days
Death 1.4 1.0 0.19
Cardiac death 1.2 0.8 0.25
Myocardial infarction 8.7 5.7 0.0001
Q-wave 1.2 1.0 0.39
Non–Q-wave 7.4 4.8 0.0001
Unplanned revascularization 3.8 3.4 0.50
MACE 11.9 8.2 0.0001
Non-CABG major bleeding 6.3 5.9 0.54
CABG major bleeding — — 0.68
NACE 16.2 12.7 0.0005
At 1 year
Death 5.3 3.2 0.0001
Cardiac death 3.0 1.8 0.002
Myocardial infarction 13.5 8.2 0.0001
Q-wave 1.6 1.8 0.94
Non–Q-wave 12.1 6.5 0.0001
Unplanned revascularization 17.3 11.7 0.0001
MACE 27.8 18.1 0.0001
Values are %.Abbreviations as in Tables 1, 2, and 3.ACS is common after CABG. In the Veterans Admin-
istration Cooperative Study of Coronary Artery Bypass
Surgery, approximately 1 in 3 patients had an MI within 10
and ACS Triaged to PCI, CABG, or Medical Management
Medical
Management
(n  1,032) P1 P2 P3
1.7 0.0001 0.60 0.0003
1.3 0.0007 0.0001 0.0001
0.2 0.038 0.004 0.0005
1.1 0.006 0.0001 0.0001
2.1 0.11 0.02 0.19
4.4 0.0001 0.0001 0.0001
2.6 0.09 0.0001 0.52
6.3 0.004 0.0001 0.0001
4.9 0.0006 0.64 0.0003
4.6 0.038 0.0001 0.0001
0.6 0.08 0.03 0.0005
4.1 0.14 0.0001 0.0001
7.7 0.30 0.0001 0.19
14.3 0.007 0.0001 0.0001
 PCI vs. repeat CABG; P2 PCI vs. medical management; P3 CABG
BG Triaged to PCI, (Repeat) CABG, or Medical Treatment
ts Triaged to CABG
(n  1,537)
p Value
Patients Triaged to Medical
Treatment (n  4,464)
p Value
CABG
73)
First CABG
(n  1,464)
Prior CABG
(n  1,032)
No Prior CABG
(n  3,432)
4 3.6 0.0001 1.7 1.4 0.63
4 3.4 0.0001 1.2 1.0 0.65
2 11.1 0.008 1.3 0.9 0.23
4 3.6 0.79 0.2 0.2 0.94
.8 7.6 0.003 1.1 0.7 0.17
0 1.6 0.29 2.1 1.0 0.005
.8 14.2 0.0004 4.4 2.8 0.01
5 3.5 0.34 2.6 3.1 0.47
.6 53.3 0.21 0.1 0.5 0.07
.1 16.8 0.003 6.3 5.3 0.24
.8 6.3 0.006 4.9 4.1 0.13
.8 4.5 0.0002 2.8 2.3 0.18
.2 11.8 0.014 4.6 2.2 0.0001
.4 3.7 0.81 0.6 0.4 0.47
.8 8.4 0.008 4.1 1.8 0.0001
.1 3.9 0.005 7.7 3.4 0.0001
.2 19.1 0.0001 14.3 8.1 0.0001CABG
t CABG
73)
.4
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924years after CABG (3). In recent ACS reports, 12% to 22%
of patients had prior CABG (11–16). In ACUITY, in
which nearly 14,000 patients with moderate- and high-risk
ACS were enrolled from 450 sites from 17 countries, 18% of
patients had previously undergone CABG, which is consis-
tent with these recent reports.
Clinical outcomes at 1 year in ACUITY were signifi-
cantly worse in patients with prior CABG both by univar-
iate and by multivariable analysis. Approximately 1 in 5
patients with prior CABG experienced a recurrent MACE
by 1 year. Multiple factors underlie the poor prognosis of
patients with prior CABG and ACS. Of note is the
high-risk clinical profile of the prior CABG cohort, includ-
ing older age, numerous comorbidities, and worse left
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Figure 3. Outcomes of Patients With Prior CABG Randomized to Alterna-
tive Antithrombotic Regimens at 30 Days and 1 Year
Outcomes of patients with prior CABG randomized to alternative anti-
thrombotic regimens at 30 days (A) and 1 year (B). GPI  glycoprotein
IIb/IIIa inhibitor; other abbreviations as in Figure 1.ventricular function, which clearly contributed to adverseprognosis. More frequent occurrence of late MI and un-
planned revascularization reflect more extensive atheroscle-
rotic burden in the prior CABG cohort.
In addition, PCI of bypass graft conduits was associated
with higher MACE rates than PCI in native coronary arteries,
re-emphasizing that PCI of bypass grafts (especially saphenous
vein grafts) (17) should be avoided if possible (i.e., look for
alternative pathways for PCI in the native coronary arteries).
Moreover, the use of arterial conduits was notably infrequent in
ACS patients with prior CABG undergoing repeat CABG,
likely due to clinical and anatomic factors (including urgency of
reoperation, hemodynamic instability, and prior use of arterial
grafts). Reoperation for bleeding and transfusions were also
more common in patients undergoing repeat rather than
first-time CABG. Thus, the early and late results of both
repeat CABG and PCI in ACS are not as favorable as
first-time surgery (18,19); this is consistent with prior reports
in non-ACS patients (20,21).
Of note, triage to PCI, CABG, or medical therapy in
ACUITY was not randomized, and the optimal manage-
ment strategy when patients with prior CABG present with
ACS remains undetermined. There was wide disparity in
outcomes both between the triage arms and inside the
medically treated patients stratified by reason to decline
revascularization. The 6-month mortality of 3,853 ACS
patients with prior CABG in the GRACE (Global Registry
of Acute Coronary Events) was lower in patients revascu-
larized versus those treated medically by univariate but not
by multivariable analysis (14). In a larger Swedish registry of
10,837 patients with previous CABG, 1-year adjusted
mortality was 50% lower with revascularization compared
with medical management (16). In the AWESOME (An-
gina With Extremely Serious Operative Mortality Evalua-
tion) trial, 3-year survival and freedom from recurrent ACS
was similar among patients with prior CABG and refractory
myocardial ischemia randomized to repeat CABG versus
PCI, although they favored PCI in the patient-choice
registry (18). In the present study, adjusted 30-day and
1-year rates of MACE were increased in patients treated
with revascularization rather than medically. However, as all
patients underwent angiography, it is likely that unmeasured
confounders remain unaccounted for that guided the deci-
sion whether to revascularize. ACUITY thus highlights the
poor prognosis of patients with prior CABG and ACS,
regardless of the treatment pathway selected after angiog-
raphy, and emphasizes the need for additional studies to
refine optimal therapeutic approaches according to individual
patient characteristics. These considerations notwithstanding,
optimal medical therapy is of paramount importance whether
revascularization is performed; intensive low-density lipopro-
tein cholesterol lowering in patients with previous CABG
significantly reduced MACE and the need for repeat revascu-
larization in 2 separate randomized trials (22,23). In ACUITY,
at 1-year follow-up, the proportion of patients receiving statins
ated
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925(78%) and other medications known to improve long-term
outcomes in ACS was surprisingly low.
Finally, the optimal antithrombotic regimen for patients
with ACS and prior CABG is not known, and existing data
are conflicting. The impact of GPI in patients with ACS
and prior CABG has been previously addressed in 2 post
hoc analyses from the randomized trials, with opposite
results (12,13). In ACUITY, by multivariable analysis, there
were no significant differences in the 30-day or 1-year rates
of MACE in patients with prior CABG treated with
heparin plus a GPI or bivalirudin monotherapy.
Study limitations. Analysis of patients with a history of
CABG was not pre-specified in the original trial design;
therefore, these results should be considered hypothesis-
generating. Important prognostic information related to
CABG, such as the age, number, and type of bypass grafts, was
not available. Triage to PCI, CABG, or medical management
was determined on the basis of operator’s discretion, and these
results may vary between different operators and institutions.
Follow-up longer than 1 year is necessary to fully characterize
the outcomes of patients with ACS and prior CABG after
different management strategies. Finally, a large-scale, ran-
domized trial is necessary to truly determine the optimal
Triage to CABG vs. medical therapy 
Triage to PCI vs. medical therapy 
LVEF 
ST-segment deviation ≥1mm 
Age 
Bivalirudin vs. UFH+GPI 
0.1 
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Triage to CABG vs. medical therapy 
Triage to PCI vs. medical therapy 
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Figure 4. Multivariable Predictors of 30-Day and 1-Year MACE in Patients
Multivariable predictors of 30-day (A) and 1-year (B) MACE in patients with pr
OR  odds ratio; PCI  percutaneous coronary intervention; UFH  unfractionmanagement strategy for patients with prior CABG and ACS.Conclusions
In the ACUITY trial, in which contemporary drugs and
devices were used, patients with prior CABG presenting
with ACS undergoing an early invasive strategy had a
substantially worse prognosis than patients without prior
CABG, especially if PCI or (repeat) CABG was required.
Although bivalirudin monotherapy was an acceptable treat-
ment for these patients, it did not improve their short-term
or long-term prognoses. Further studies are required to
identify therapeutic approaches to reduce MACE in pa-
tients with prior CABG and ACS.
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